FDA OKs Maintenance Option for High-Risk Neuroblastoma Eflornithine approved to reduce relapse risk in both kids and adults Dec 14, 2023
'Half-Matched' BMTs Effective in Severe Sickle Cell Disease High survival rates observed in patients not normally suitable for transplant Dec 13, 2023
Lenvatinib-Pembrolizumab Combo Misses Goal in First-Line HCC Trial Numerical advantages in OS, PFS fall short of statistical significance Dec 13, 2023
EUS-Guided Gastroenterostomy Better Option for Cancer-Related Duodenal Blockages However, technique and technology are not widespread Dec 08, 2023
Detecting Ovarian Cancer Early; Allergy Med for NSCLC? Bad News for Anti-TIGIT Drug News, features, and commentary about cancer-related issues Dec 07, 2023
Novel Therapy Reduced Transfusion Dependence in Lower-Risk MDS 40% of patients treated with imetelstat were transfusion-free for at least 8 weeks Dec 04, 2023
First Gene Therapy for Non-Muscle-Invasive Bladder Cancer Offers Durable Response A quarter patients with high-risk, BCG-unresponsive disease were recurrence free at 3 years Dec 04, 2023
Charting the Course: From Young Adult Leukemia Patient to Oncologist My experience shaped how I care for patients today Dec 03, 2023
Let's Talk Drug Prices; Restoring the Sense of Touch; Learning From Tumors in a Dish News, features, and commentary about cancer-related issues Dec 01, 2023
Oncolytic Virus Shows High Response Rates in BCG-Unresponsive Bladder Cancer Results from interim analysis suggest "potential to disrupt the NMIBC treatment landscape" Dec 01, 2023
Noninvasive Therapy Shows Efficacy in Non-Muscle-Invasive Bladder Cancer Investigational intravesical solution led to complete response rate of 79% Nov 30, 2023
Combining Immunotherapy and PARP Inhibition in Advanced Uterine Cancer And our roundtable of experts discuss selinexor for wild-type p53 disease Nov 30, 2023 video
FDA Approves First Therapy for Progressive Desmoid Tumors Nirogacestat reduced the risk of disease progression or death by 71% in randomized trial Nov 28, 2023
Chemoimmunotherapy Improves Pathologic Outcomes in Gastroesophageal Carcinoma Adding atezolizumab to FLOT led to more downstaging, complete regressions versus chemo alone Nov 24, 2023
Cancer Drug Recall; Long COVID and Reinfection; WHO Staffer Killed in Gaza Health news and commentary from around the Web gathered by ทฌวัษ็ว๘app staff Nov 22, 2023
Nudging Parents Plus Auditing Providers Increased HPV Vaccine Uptake in Tweens Interventions worked best in combination, according to cluster randomized trial Nov 20, 2023
Shooting at Psych Hospital; Rosalynn Carter Dies; Millions in Medical Debt Canceled Health news and commentary from around the Web gathered by ทฌวัษ็ว๘app staff Nov 20, 2023
Reprogramming Tumors; Bad Stool Samples; Human Experiences in Cancer Care News, features, and commentary about cancer-related issues Nov 17, 2023
Pancreatic Cancer Doesn't Have to Be a Death Sentence Early detection is the key to increasing survival rates Nov 13, 2023
Zoonotic Spillovers; DNA and RNA Testing for Cancer Risk Also in TTHealthWatch: genes and health conditions among Icelanders Nov 11, 2023 podcast
Vitamin D for Neuropathy; Good & Bad News for CAR-T; New Labeling for Surgical Mesh News, features, and commentary about cancer-related issues Nov 10, 2023
Moving Beyond the 'Angelina Jolie Effect' to Address Cancer Disparities A "local heroes effect" can better reach communities of color Nov 09, 2023
Novel Therapies Show Early Promise in Advanced Gastroesophageal Cancers Results look good, but more data needed Nov 08, 2023
Senate Confirms Monica Bertagnolli as Next NIH Director Vote was 62-36 in favor of the current National Cancer Institute director Nov 07, 2023
FDA Panel Backs High-Risk Designation for Salvaged Blood Irradiators With Class III designation, sponsors would have to prove safety, efficacy with randomized trials Nov 07, 2023
T-DXd Tied to Encouraging Survival in HER2-Expressing Gyn Cancers More responses, longer OS in subset with the highest levels of HER2 expression Nov 07, 2023
Maintenance Selinexor May Boost PFS in TP53 Wild-Type Advanced Endometrial Cancer Particularly strong PFS signal seen in patients that were mismatch repair proficient Nov 05, 2023
Evidence of Safety, Efficacy for Salvaged Blood Irradiators Lacking, FDA Staff Say Devices are aimed at preventing metastasis during surgery Nov 03, 2023
Wearables as Cancer Monitors; No China Price Break; Cancer Mystery in Appalachia News, features, and commentary about cancer-related issues Nov 03, 2023
Transitioning Cancer Survivors Away From Oncologic Care It's time for a new model of care Nov 03, 2023
Years of Progressing Facial Numbness and Deteriorating Vision Drives Diagnosis Suspect perineural recurrence of cutaneous squamous cell carcinoma, experts urge Nov 02, 2023
Potential Cure for Sickle Cell Clears Hurdle for Approval FDA advisors suggest the benefits of gene therapy outweigh risks of off-target editing Oct 31, 2023
FDA Reviewers Question Safety of Sickle Cell Gene Therapy Efficacy results "strongly positive," but unintended off-target effects a question Oct 30, 2023
FDA OKs First Drug for Nasopharyngeal Carcinoma Toripalimab approved in combination with first-line chemo, and as monotherapy after progression Oct 30, 2023
Wegovy and Thyroid Cancer; Maine Shooter's Mental Health; 469 Heat Deaths Health news and commentary from around the Web gathered by ทฌวัษ็ว๘app staff Oct 30, 2023
Soap to Fight Skin Cancer; $1,000 Early Cancer Detection Test; FDA Approval in MDS News, features, and commentary about cancer-related issues Oct 27, 2023
More Data Support Adding Immunotherapy to Chemo in Advanced Endometrial Cancer PFS doubled and OS improved, driven by mismatch repair-deficient disease Oct 23, 2023
Is It a Sports Injury, or Something More Serious? Osteoscarcomas can present to any clinical setting, pediatric researcher says Oct 23, 2023
RET Inhibitor Posts Frontline Wins in Medullary Thyroid Cancer, NSCLC Two randomized studies demonstrate significantly improved PFS against standard regimens Oct 22, 2023
Landmark Trial Produces New First-Line Standard for Advanced Bladder Cancer Enfortumab vedotin-pembrolizumab doubles OS, PFS versus chemotherapy Oct 22, 2023
